{
    "nct_id": "NCT06291415",
    "official_title": "A Multicenter, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523, a Syk Inhibitor, in Adult Subjects With Immune Thrombocytopenia",
    "inclusion_criteria": "Subjects may be enrolled in this study only if they satisfy all the following criteria:\n\n1. Adult male or female subjects ≥18 years of age\n2. Diagnosis of ITP, with a duration of disease of at least 3 months prior to randomization or enrollment\n3. Intolerance or insufficient response or recurrence after at least 1 prior ITP treatment (excluding splenectomy)\n4. Response (defined as achieved a platelet count ≥50 × 109/L) to at least 1 prior ITP therapy (including splenectomy)\n5. Adequate hematologic, hepatic and renal function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Subjects are not eligible for enrollment into this study if any one of the following criteria are met:\n\n1. Evidence of the presence of secondary causes of ITP\n2. Clinically serious hemorrhage requiring immediate adjustment of platelets\n3. Known history of vital organ transplantation or hematopoietic stem-cell transplantation or chimeric antigen receptor T-cells (CAR-T) therapy\n4. Splenectomy within 12 weeks prior to enrollment\n5. Presence of active malignancy unless deemed cured by adequate treatment.\n6. History of serious cardiovascular disease corrected QT interval (QTcF) ≥450 ms\n7. Uncontrolled hypertension\n8. Being unsuitable to participate in this study as considered by investigators",
    "miscellaneous_criteria": ""
}